Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Brokerages

Atossa Genetics Inc. (NASDAQ:ATOS) has earned an average recommendation of “Hold” from the five research firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $20.3333.

ATOS has been the subject of several recent analyst reports. Rodman & Renshaw began coverage on shares of Atossa Genetics in a research note on Tuesday. They set a “buy” rating and a $12.00 price objective for the company. HC Wainwright increased their target price on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings downgraded shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Finally, Ascendiant Capital Markets reduced their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th.

Atossa Genetics Stock Up 0.4%

ATOS traded up $0.01 during trading on Tuesday, reaching $2.29. 97,073 shares of the company were exchanged, compared to its average volume of 138,711. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $19.35. The company’s 50-day moving average is $4.00 and its two-hundred day moving average is $5.72. The company has a market cap of $19.72 million, a price-to-earnings ratio of -0.71 and a beta of 1.25.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). Equities analysts forecast that Atossa Genetics will post -4.3 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

Large investors have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. bought a new position in Atossa Genetics in the 2nd quarter worth about $2,468,000. Renaissance Technologies LLC boosted its position in shares of Atossa Genetics by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after acquiring an additional 514,175 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Atossa Genetics during the second quarter worth about $381,000. Qube Research & Technologies Ltd grew its holdings in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after purchasing an additional 325,340 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after purchasing an additional 245,717 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.